BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 35217883)

  • 1. Event-free survival after
    Ceci F; Rovera G; Iorio GC; Guarneri A; Chiofalo V; Passera R; Oderda M; Dall'Armellina S; Liberini V; Grimaldi S; Bellò M; Gontero P; Ricardi U; Deandreis D
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(9):3257-3268. PubMed ID: 35217883
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Deandreis D; Guarneri A; Ceci F; Lillaz B; Bartoncini S; Oderda M; Nicolotti DG; Pilati E; Passera R; Zitella A; Bellò M; Parise R; Carlevato R; Ricardi U; Gontero P
    Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2804-2815. PubMed ID: 32314028
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Ceci F; Castellucci P; Graziani T; Farolfi A; Fonti C; Lodi F; Fanti S
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):31-39. PubMed ID: 30350010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy.
    Schmidt-Hegemann NS; Fendler WP; Ilhan H; Herlemann A; Buchner A; Stief C; Eze C; Rogowski P; Li M; Bartenstein P; Ganswindt U; Belka C
    Radiat Oncol; 2018 Mar; 13(1):37. PubMed ID: 29499730
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Calais J; Ceci F; Eiber M; Hope TA; Hofman MS; Rischpler C; Bach-Gansmo T; Nanni C; Savir-Baruch B; Elashoff D; Grogan T; Dahlbom M; Slavik R; Gartmann J; Nguyen K; Lok V; Jadvar H; Kishan AU; Rettig MB; Reiter RE; Fendler WP; Czernin J
    Lancet Oncol; 2019 Sep; 20(9):1286-1294. PubMed ID: 31375469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?
    Ceci F; Uprimny C; Nilica B; Geraldo L; Kendler D; Kroiss A; Bektic J; Horninger W; Lukas P; Decristoforo C; Castellucci P; Fanti S; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1284-94. PubMed ID: 25975367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Calais J; Czernin J; Cao M; Kishan AU; Hegde JV; Shaverdian N; Sandler K; Chu FI; King CR; Steinberg ML; Rauscher I; Schmidt-Hegemann NS; Poeppel T; Hetkamp P; Ceci F; Herrmann K; Fendler WP; Eiber M; Nickols NG
    J Nucl Med; 2018 Feb; 59(2):230-237. PubMed ID: 29123013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
    Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups.
    Roberts MJ; Chatfield MD; Hruby G; Nandurkar R; Roach P; Watts JA; Cusick T; Kneebone A; Eade T; Ho B; Nguyen A; Tang C; McCarthy M; Francis R; Stricker P; Emmett L
    BJU Int; 2022 Nov; 130 Suppl 3(Suppl 3):32-39. PubMed ID: 35488182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The management impact of
    Kulkarni M; Hughes S; Mallia A; Gibson V; Young J; Aggarwal A; Morris S; Challacombe B; Popert R; Brown C; Cathcart P; Dasgupta P; Warbey VS; Cook GJR
    Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):674-686. PubMed ID: 31872280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy.
    Rogowski P; Trapp C; von Bestenbostel R; Eze C; Ganswindt U; Li M; Unterrainer M; Zacherl MJ; Ilhan H; Beyer L; Kretschmer A; Bartenstein P; Stief C; Belka C; Schmidt-Hegemann NS
    Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1417-1428. PubMed ID: 34628521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Outcomes from
    Emmett L; van Leeuwen PJ; Nandurkar R; Scheltema MJ; Cusick T; Hruby G; Kneebone A; Eade T; Fogarty G; Jagavkar R; Nguyen Q; Ho B; Joshua AM; Stricker P
    J Nucl Med; 2017 Dec; 58(12):1972-1976. PubMed ID: 28747524
    [No Abstract]   [Full Text] [Related]  

  • 14.
    Farolfi A; Ceci F; Castellucci P; Graziani T; Siepe G; Lambertini A; Schiavina R; Lodi F; Morganti AG; Fanti S
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):11-19. PubMed ID: 29905907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment.
    van Leeuwen PJ; Stricker P; Hruby G; Kneebone A; Ting F; Thompson B; Nguyen Q; Ho B; Emmett L
    BJU Int; 2016 May; 117(5):732-9. PubMed ID: 26683282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Multicenter Prospective Clinical Trial of
    McCarthy M; Francis R; Tang C; Watts J; Campbell A
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):801-808. PubMed ID: 30890448
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Akdemir EN; Tuncel M; Akyol F; Bilen CY; Baydar DE; Karabulut E; Ozen H; Caglar M
    World J Urol; 2019 May; 37(5):813-821. PubMed ID: 30151600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of
    Raveenthiran S; Yaxley J; Gianduzzo T; Kua B; McEwan L; Wong D; Tsang G; MacKean J
    Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):385-390. PubMed ID: 31363165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection Efficacy of Hybrid
    Einspieler I; Rauscher I; Düwel C; Krönke M; Rischpler C; Habl G; Dewes S; Ott A; Wester HJ; Schwaiger M; Maurer T; Eiber M
    J Nucl Med; 2017 Jul; 58(7):1081-1087. PubMed ID: 28209912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy.
    Adebahr S; Althaus A; Scharl S; Strouthos I; Farolfi A; Serani F; Lanzafame H; Trapp C; Koerber SA; Peeken JC; Vogel MME; Vrachimis A; Spohn SKB; Grosu AL; Kroeze SGC; Guckenberger M; Fanti S; Hruby G; Emmett L; Belka C; Schmidt-Hegemann NS; Henkenberens C; Aebersold DM; Wiegel T; Afshar-Oromieh A; Zamboglou C; Shelan M
    Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):558-567. PubMed ID: 37736808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.